Core Life Analytics, a Utrecht founded AI startup will, thanks to new investments, accelerate the development of StratoMineR, a data analysis platform for the development of new medicines. BOM Brabant Ventures, Utrecht Holdings, and TechFund One together invest 1 million euros in the company. Core Life Analytics is moving its headquarters to Den Bosch to make use of the knowledge networks around the Jheronimus Academy of Data Science and Pivot Park in Oss.
With StratoMineR, biologists can analyze complex datasets that are used in the development of new medicines. Scientists from renowned companies such as Pfizer, Janssen, and Galapagos are now using the software.
With the new growth money, Core Life Analytics wants to accelerate product development. “With this investment, we can expand our development team and speed up the software development process by working on multiple modules at the same time,” says CTO Wienand Omta. Core Life Analytics will also use the money to strengthen its marketing & sales activities. CEO David Egan: “We are pleased to have a team that not only supports us financially but also advises and has a huge network”.
Sjoerd van Gorp of BOM Brabant Ventures emphasizes the importance of a product like StratoMineR: “By unlocking hidden information in increasingly complex biological datasets, new innovative medicines can be developed. We are very impressed with the steps taken by the Core Life Analytics team. We are therefore delighted that the company will become part of the rapidly growing life science ecosystem in Brabant and the data science knowledge network in Den Bosch”.
Core Life Analytics developed the tool in the University Medical Center Utrecht. Oscar Schoots, director of Utrecht Holdings, notes that the product has already been converted into a viable product with a growing customer base. “We are very pleased that with this Series A deal, the company is taking the next step to further develop this world-class data analysis solution from the UMCU.”
Peter van Meersbergen of TechFund One places the investment in a greater whole: “The technology and innovative business model offer new opportunities for life science and pharmaceutical companies to analyze their research data better and faster. The global search for vaccines and therapies for Covid-19 underlines the importance of this”.